Building A Better Biomarker Test

In 2012, the FDA approved Amyvid dye, the first Alzheimer’s biomarker test. But the dye requires a PET scan and costs thousands of dollars. 

Researchers are looking for better biomarkers for earlier diagnosis and improved drug research. The tau protein, for example, is easier to detect. Inflammation is another key signal, though researchers are still investigating measurable biomarkers. Finding a biomarker to detect weakening synapses between brain cells could be the diagnostic payoff. 

Biomarkers are not accurate measurements of mental function but earlier diagnosis and targeted treatment of symptoms may help delay or even stop memory changes. 

NPR

Secondary Topic
Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top